Read by QxMD icon Read


Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Patricia Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk Seo, David J Witt, Michael J Silverberg
BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen. METHODS: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naïve, no cirrhosis, no HIV infection, level of HCV RNA <6 million IU/mL) and were treated for 8 or 12 weeks from October 2014 through December 2016...
March 10, 2018: Clinical Gastroenterology and Hepatology
Xihui Jiang, Ya Wang, Zhengyan Su, Fang Yang, Houning Lv, Lin Lin, Chao Sun
We aimed to investigate the relationship between the histologic severity and red blood cell distribution width to platelet ratio (RPR) in patients with primary biliary cholangitis (PBC). One hundred and seven consecutive patients with liver biopsy-proven and as yet treatment-naïve PBC were enrolled as the primary and validation cohort. The histologic stages were divided into early stage (Scheuer's stage 1 & 2) and late stage (Scheuer's stage 3 & 4). The overall patient demographics, clinical manifestations, hematological tests and biochemical profile were retrospectively collected from our database...
March 13, 2018: Scandinavian Journal of Clinical and Laboratory Investigation
Hiroki Ikeda, Tsunamasa Watanabe, Hirohito Shimizu, Tetsuya Hiraishi, Rena Kaneko, Toshiyuki Baba, Hideaki Takahashi, Kotaro Matsunaga, Nobuyuki Matsumoto, Hiroshi Yasuda, Chiaki Okuse, Shogo Iwabuchi, Michihiro Suzuki, Fumio Itoh
AIM: The therapeutic benefit of adding ribavirin (RBV) to 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) for patients who experienced failure of a previous nonstructural protein (NS) 5A inhibitor-containing regimen is unclear. METHODS: A total of 29 genotype 1b HCV patients who had failed prior daclatasvir (DCV) plus asunaprevir (ASV) treatment were retreated for 12 weeks of LDV/SOF, with or without RBV. Antiviral efficacy and predictive factors associating with a sustained virological response at 24 weeks (SVR24) were evaluated retrospectively...
March 5, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Norio Akuta, Joji Toyota, Yoshiyasu Karino, Fusao Ikeda, Akio Ido, Katsuaki Tanaka, Koichi Takaguchi, Atsushi Naganuma, Eiichi Tomita, Kazuaki Chayama, Shigetoshi Fujiyama, Yukiko Inada, Hitoshi Yoshiji, Hideaki Watanabe, Hiroki Ishikawa, Fiona McPhee, Stephanie Noviello, Hiromitsu Kumada
BACKGROUND: In the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). As HCV clearance may improve liver outcomes, we assessed hepatic fibrosis and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post-treatment in UNITY-3. METHODS: Treatment-naive or interferon-experienced UNITY-3 patients with HCV GT-1 who received twice-daily DCV-TRIO were assessed for fibrosis [FibroTest; FibroScan; fibrosis-4 index (FIB-4), aspartate-aminotransferase-to-platelet-ratio index] and AFP at baseline and Weeks 4 (FIB-4 only), 12 or 24 post-treatment...
March 2, 2018: Journal of Gastroenterology
Ahmed Cordie, Ahmed Salama, Marwa El-Sharkawy, Saeed M El-Nahaas, Marwa Khairy, Aisha Elsharkawy, Mohamed Hassany, Gamal Esmat
BACKGROUND: Assessment of hepatic fibrosis in chronic hepatitis C virus patients by liver biopsy is not widely accepted despite its accuracy, being invasive, carrying complications and adding cost. This paved the way to development and use of non-invasive markers of fibrosis in diagnosis of hepatic fibrosis. AIM: Evaluating the efficiency of Fib-4, Egy-score, Aspartate-to-platelet ratio index (APRI) and Göteborg University Cirrhosis Index (GUCI) in comparison to liver biopsy, in the assessment of hepatic fibrosis in chronic hepatitis C patients Methods: Cross sectional study including 200 chronic HCV patients were divided into two groups according to stage of fibrosis (Metavir score) into non-significant fibrosis (<F2) and significant fibrosis (≥F2)...
February 24, 2018: Journal of Medical Virology
Yuji Eso, Atsushi Takai, Kojiro Taura, Ken Takahashi, Yoshihide Ueda, Hiroyuki Marusawa, Hiroshi Seno
BACKGROUND AND AIM: Mac-2-binding protein glycosylation isomer (M2BPGi) was recently identified as a serum glycobiomarker for liver fibrosis. However, the relationship between M2BPGi and malnutrition in patients with chronic liver disease (CLD) is unknown. We aimed to evaluate whether M2BPGi could be a surrogate marker for malnutrition in patients with CLD. METHODS: In total, 338 outpatients with CLD were enrolled (median age: 67 years). We evaluated the associations among liver fibrosis markers (M2BPGi, FIB-4 index, and aspartate aminotransferase to platelet count ratio index), Child-Pugh stages, and nutritional status markers...
February 22, 2018: Journal of Gastroenterology and Hepatology
I Barchetta, F A Cimini, R De Gioannis, G Ciccarelli, L Bertoccini, A Lenzi, M G Baroni, M G Cavallo
AIMS: Procollagen-III peptide (PIIINP) is a marker of fibrosis associated with increased cardio-metabolic risk and progression of chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH); its association with type 2 diabetes mellitus has not been elucidated yet. Aim of this study was to investigate the relationship between circulating PIIINP levels, metabolic traits and body fat distribution in subjects with T2DM with or without NAFLD. MATERIALS AND METHODS: Data from sixty-two T2DM subjects recruited in our Diabetes outpatient clinics at Sapienza University of Rome, Italy, were analysed...
February 22, 2018: Diabetes/metabolism Research and Reviews
Letícia de Paula Scalioni, Betânia Rodrigues Dos Santos, Poli Mara Spritzer, Cristiane Alves Villela-Nogueira, Lia Laura Lewis-Ximenez, Priscila Pollo-Flores, Eliane Bordalo Cathalá Esberard, Carlos Eduardo Brandão-Mello, Elisabeth Lampe, Livia Melo Villar
Potential relationship of vitamin D, vitamin D receptor (VDR), and vitamin D binding protein (DBP) have been suggested in the pathophysiology of hepatitis C virus (HCV) infection. The aim of this observational study is to determine vitamin D levels, and VDR and DBP genetic polymorphism according demographic and laboratory data in chronic HCV patients (CHC).A total of 148 CHC patients gave serum samples for testing 25-hydroxyvitamin D (25 (OH)D) level by immunochemiluminometric assay (<20 ng/mL defined as deficient) and donated blood samples to allelic discrimination analysis using TaqMan assays...
February 2018: Medicine (Baltimore)
Yingyu Zhang, Ying Shi, Ruihong Wu, Xiaomei Wang, Xiuzhu Gao, Junqi Niu
OBJECTIVES: The aim of this study was to evaluate the association between previous hepatitis B virus (HBV) infection and the severity of primary biliary cholangitis (PBC). PATIENTS AND METHODS: A total of 379 HBsAg-negative PBC patients were investigated between 2012 and 2017 in this study. Fifty-two of these patients underwent liver biopsy. The enrolled patients were divided into an anti-HBc-positive group and an anti-HBc-negative group; the patients with liver biopsy were further divided into early stage (stage I) and advanced stage (stages II, III, and IV) according to histological assessment...
February 16, 2018: European Journal of Gastroenterology & Hepatology
Llorenç Caballería, Guillem Pera, Ingrid Arteaga, Lluís Rodríguez, Alba Alumà, Rosa Ma Morillas, Napoleón de la Ossa, Alba Díaz, Carmen Expósito, Dolores Miranda, Carmen Sánchez, Rosa Ma Prats, Marta Urquizu, Angels Salgado, Magda Alemany, Alba Martinez, Irfan Majeed, Núria Fabrellas, Isabel Graupera, Ramón Planas, Isabel Ojanguren, Miquel Serra, Pere Torán, Juan Caballería, Pere Ginès
BACKGROUND AND AIMS: Liver fibrosis is the main determinant of long-term outcome in chronic liver diseases. Little is known about prevalence of liver fibrosis in general population. Aim of the study was to investigate the prevalence of liver fibrosis in general adult population with unknown liver disease. METHODS: Population-based, cross-sectional study, performed in Barcelona metropolitan area. Subjects aged 18-75yr were identified randomly from citizens included in primary health care registry...
February 13, 2018: Clinical Gastroenterology and Hepatology
Zhongfeng Wang, Xu Liu, Hongqin Xu, Limei Qu, Dezhi Zhang, Pujun Gao
The aim of this study was to evaluate the ability of noninvasive markers to identify the histological severity of primary biliary cholangitis (PBC).Fifty-eight treatment-naïve PBC patients who had undergone liver biopsy were enrolled in our study. The patients' histological stages were based on the classifications of Ludwig and Scheuer. Aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on the 4 factors (FIB-4), red blood cell distribution width to platelet ratio (RPR), and platelet count to spleen thickness (PC/ST) ratio were calculated...
February 2018: Medicine (Baltimore)
Laurent Castera
Non-alcoholic fatty liver disease is a major cause of liver disease worldwide and the most common liver disorder in Western countries, affecting around 25% of the general population. Fibrosis is the major long-term histological prognostic criteria of this disease. Liver biopsy cannot be realistically performed in such a huge population and, moreover, has well-known limitations (invasiveness, rare but potentially life-threatening complications and sampling variability). Over the past decade, there has been a growing interest in alternative novel strategies for the non-invasive evaluation of fibrosis...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Christopher Sung-Huan Yeh, Chao-Wei Hsu, Kung-Hao Liang, Yi-Cheng Chen, Chih-Lang Lin, Rong-Nan Chien, Tsung-Hui Hu, Wey-Ran Lin, Ming-Wei Lai, Yu-De Chu, Chau-Ting Yeh
BACKGROUND AND AIM: Commonly used non-invasive fibrosis scores usually included serum transaminase levels in the equations, including aspartate-to-platelet-ratio-index (APRI) and fibrosis-4 (FIB-4). Transaminases fluctuated significantly in chronic hepatitis B (CHB) patients with exacerbations, leading to unsteady score values. As such, here, we aim to develop a transaminase-free score suitable for pretherapeutic evaluation of fibrosis stages. METHODS: Firstly, 1082 treatment-naïve CHB patients were enrolled and divided into modeling (n = 541) and verification (n = 541) cohorts...
February 8, 2018: Journal of Gastroenterology and Hepatology
Mohammed Tag-Adeen, Maha Zeinelabedin Omar, Fatma Mohamed Abd-Elsalam, Ali Hasaneen, Mohamed Ahmed Mohamed, Hala Mohamed Elfeky, Ebada Mohamed Said, Badawy Abdul-Aziz, Amira Hefney Osman, Enas Sebaey Ahmed, Ghada Sidky Osman, Taghreed Abdul-Samie
Fibrosis assessment in chronic hepatitis B (CHB) is essential for prediction of long-term prognosis and proper treatment decision. This study was conducted to assess predictability of 5 simple noninvasive fibrosis indexes in comparison to liver biopsy in CHB patients.A total of 200 CHB adult Egyptian patients were consecutively included in this study, all were subjected to liver biopsy with staging of fibrosis using METAVIR scoring system. Fibrosis indexes including S-index, red cell distribution width to platelets ratio index (RPR), fibrosis-4 index (Fib-4), AST to platelets ratio index (APRI), and AST/ALT ratio index (AAR) were compared to biopsy result and their predictabilities for the different fibrosis stages were assessed using area under receiver operating characteristic curve (AUROC) analysis...
February 2018: Medicine (Baltimore)
Zaixing Yang, Yan Liang, Feng Lin, Zhencheng Zhang, Wanwan Luo, Yuting Zhang, Renqian Zhong
BACKGROUND: Stromal cell-derived factor-1 (SDF-1), also called chemokine (C-X-C motif) ligand 12 (CXCL12), as a chemokine for premature B cells, T cells and monocytes, is detected in liver, pancreas, spleen and heart. However, its diagnostic value for primary biliary cholangitis (PBC) as well as the association of SDF-1 with inflammatory and fibrotic progression is unclear. The aim of this study was to determine serum stromal cell-derived factor-1 (SDF-1) level and to explore its diagnostic value for primary biliary cholangitis (PBC) as well as the association of SDF-1 with inflammatory and fibrotic progression of PBC...
February 2, 2018: International Immunopharmacology
Andrea Dória Batista, Carlos Jonnatan Pimentel Barros, Tássia Brena Barroso Carneiro Costa, Michele Maria Gonçalves de Godoy, Ronaldo Dionísio Silva, Joelma Carvalho Santos, Mariana Montenegro de Melo Lira, Norma Thomé Jucá, Edmundo Pessoa de Almeida Lopes, Ricardo Oliveira Silva
AIM: To develop metabonomic models (MMs), using 1 H nuclear magnetic resonance (NMR) spectra of serum, to predict significant liver fibrosis (SF: Metavir ≥ F2), advanced liver fibrosis (AF: METAVIR ≥ F3) and cirrhosis (C: METAVIR = F4 or clinical cirrhosis) in chronic hepatitis C (CHC) patients. Additionally, to compare the accuracy of the MMs with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4). METHODS: Sixty-nine patients who had undergone biopsy in the previous 12 mo or had clinical cirrhosis were included...
January 27, 2018: World Journal of Hepatology
Kazuki Ohashi, Toru Ishikawa, Mitsuyuki Suzuki, Hiroko Abe, Fujiko Koyama, Tomomi Nakano, Aya Ueki, Hirohito Noguchi, Erina Hasegawa, Shiori Hirosawa, Miki Kobayashi, Hiroshi Hirosawa, Kaede Sato, Takako Fukazawa, Yuka Maruyama, Toshiaki Yoshida
Interferon-free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have shown a high rate of sustained virologic response (SVR), and a reduction in side effects during treatment is also anticipated. However, the impact of the regimens on health-related quality of life (HRQOL) and side effects during treatment is not fully understood. The purpose of the present study was to evaluate HRQOL in the clinical course of patients with CHC receiving daclatasvir/asunaprevir (DCV/ASV) therapy using the Short Form-36 (SF-36) method...
January 2018: Experimental and Therapeutic Medicine
Jing Li, Ri-Cheng Mao, Xiao-Ling Li, Jin-Wei Zheng, Xun Qi, Quan Yuan, Jun Zhang, Ji-Ming Zhang, Ning-Shao Xia
BACKGROUNDS: The evaluation of liver fibrosis stages is essential for the clinical management of chronic hepatitis B (CHB). AIMS: To develop and validate a novel noninvasive index for moderate to severe fibrosis (≥S2) in CHB patients. METHODS: A total of 401 CHB patients who underwent liver biopsy were divided into the training (n = 300) and validation (n = 101) cohort. Histological severity was scored using a modified Scheuer system...
January 5, 2018: Digestive and Liver Disease
Lisa I Backus, Pamela S Belperio, Troy A Shahoumian, Larry A Mole
The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon-free DAA treatment on all-cause mortality in hepatitis C (HCV) infected patients without advanced liver disease. This observational cohort analysis was comprised of 103,346 genotype 1, 2 and 3, HCV-monoinfected patients without advanced liver disease, defined by FIB-4 ≤3...
January 29, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Qiang Li, Liang Chen, Yu Zhou
Noninvasive fibrosis tests have been used widely for evaluation of liver fibrosis in patients with chronic hepatitis B (CHB). We aimed to investigate the influence of antiviral treatment on FibroScan, APRI, and FIB-4 in CHB patients with significant liver histological changes (SLHC) defined as inflammatory grade ≥ A2 and/or fibrosis stage ≥ F2. A total of 104 CHB patients with SLHC at the baseline were included. FibroScan, APRI, and FIB-4 values were compared before and after 3-year entecavir (ETV) treatment...
January 19, 2018: Clinical and Experimental Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"